MD20150006A2 - Inhibitori de micro-ARN din familia miR-15 - Google Patents

Inhibitori de micro-ARN din familia miR-15

Info

Publication number
MD20150006A2
MD20150006A2 MDA20150006A MD20150006A MD20150006A2 MD 20150006 A2 MD20150006 A2 MD 20150006A2 MD A20150006 A MDA20150006 A MD A20150006A MD 20150006 A MD20150006 A MD 20150006A MD 20150006 A2 MD20150006 A2 MD 20150006A2
Authority
MD
Moldova
Prior art keywords
mir
family
oligonucleotides
rnas
inhibitors
Prior art date
Application number
MDA20150006A
Other languages
English (en)
Russian (ru)
Inventor
РУЙИ Ева ВАН
Кристина ДАЛБИ
Анита Сето
Original Assignee
MiRagen Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MiRagen Therapeutics, Inc. filed Critical MiRagen Therapeutics, Inc.
Publication of MD20150006A2 publication Critical patent/MD20150006A2/ro

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/344—Position-specific modifications, e.g. on every purine, at the 3'-end
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications

Abstract

Invenţia se referă la oligonucleotide modificate chimic abile să inhibe expresia (de exemplu, cantitatea) de miARN din familia miR-15, inclusiv miR-15a, miR-15b, miR-16, miR-195, miR-424 şi miR-497. În unele variante de realizare prezenta invenţie prevede oligonucleotide abile să inhibe într-un mod specific expresia sau cantitatea de fiecare dintre miR-15a, miR-15b, miR-16, miR-195, miR-424 şi miR-497. De asemenea, invenţia se mai referă la compoziţii farmaceutice cu conţinut de oligonucleotide şi la metode de tratare a pacienţilor cu stări sau tulburări legate de sau care implică miARN din familia miR-15, cum ar fi o stare cardiovasculară. În diverse forme de realizare oligonucleotidele oferă avantaje în una sau mai multe dintre: eficacitate, eficienţă de livrare, specificitate pentru ţintă, toxicitate şi/sau stabilitate.
MDA20150006A 2012-06-21 2013-06-21 Inhibitori de micro-ARN din familia miR-15 MD20150006A2 (ro)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261662772P 2012-06-21 2012-06-21
US201361780352P 2013-03-13 2013-03-13
PCT/US2013/046960 WO2013192486A1 (en) 2012-06-21 2013-06-21 Inhibitors of the mir-15 family of micro-rnas

Publications (1)

Publication Number Publication Date
MD20150006A2 true MD20150006A2 (ro) 2015-06-30

Family

ID=49769409

Family Applications (1)

Application Number Title Priority Date Filing Date
MDA20150006A MD20150006A2 (ro) 2012-06-21 2013-06-21 Inhibitori de micro-ARN din familia miR-15

Country Status (17)

Country Link
US (1) US9163235B2 (ro)
EP (1) EP2863956A4 (ro)
JP (1) JP2015525081A (ro)
KR (1) KR20150036140A (ro)
CN (1) CN104540527A (ro)
AR (1) AR091539A1 (ro)
AU (1) AU2013277033A1 (ro)
BR (1) BR112014032239A2 (ro)
CA (1) CA2876105A1 (ro)
EA (1) EA201590070A1 (ro)
HK (1) HK1209621A1 (ro)
IN (1) IN2014DN10899A (ro)
MD (1) MD20150006A2 (ro)
MX (1) MX2014015641A (ro)
SG (1) SG11201408460UA (ro)
TW (1) TW201406774A (ro)
WO (1) WO2013192486A1 (ro)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2876180C (en) 2012-06-21 2019-11-19 MiRagen Therapeutics, Inc. Oligonucleotide-based inhibitors comprising locked nucleic acid motif
CN105189751B (zh) 2013-03-15 2019-04-23 米拉根医疗股份有限公司 桥接双环核苷
US10443044B2 (en) 2014-04-17 2019-10-15 Ips Heart Generating cardiac progenitor cells from pluripotent stem cells using isoxazole or isoxazole like compounds
US9752144B2 (en) 2014-08-04 2017-09-05 MiRagen Therapeutics, Inc. Inhibitors of MYH7B and uses thereof
MA40463A (fr) 2014-08-07 2017-06-14 Regulus Therapeutics Inc Ciblage de micro-arn pour traiter des troubles métaboliques
AU2016209386A1 (en) 2015-01-20 2017-08-03 MiRagen Therapeutics, Inc. miR-92 inhibitors and uses thereof
WO2017219170A1 (zh) * 2016-06-19 2017-12-28 毛侃琅 特异抑制人 miRNA-29a 和 miR-424 表达的慢病毒载体的构建及其应用
AU2017368050A1 (en) 2016-11-29 2019-06-20 Puretech Lyt, Inc. Exosomes for delivery of therapeutic agents
CN106692175A (zh) * 2016-12-26 2017-05-24 大连医科大学附属第二医院 miR‑665‑3p抑制物在制备防治缺血再灌注损伤药物中的应用
US10941403B2 (en) 2018-04-02 2021-03-09 Oregon Health & Science University Microrna inhibitors as anti-cancer therapeutics
US20220267778A1 (en) 2019-07-30 2022-08-25 Shionogi & Co., Ltd. Nucleic acid drug targeting murf1
US20230265426A1 (en) * 2020-07-23 2023-08-24 Johann Wolfgang Goethe-Universität Frankfurt Combinatorial inhibition of mirnas for treatment of heart failure
CN113599540B (zh) * 2021-05-27 2023-05-23 山西医科大学 miRNA-195-5p在制备抑制或降低麦芽酚铝所致神经细胞损伤的试剂中的应用

Family Cites Families (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003029459A2 (en) 2001-09-28 2003-04-10 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Micro-rna molecules
US8137910B2 (en) 2002-05-03 2012-03-20 Duke University Method of regulating gene expression
US7892793B2 (en) 2002-11-04 2011-02-22 University Of Massachusetts Allele-specific RNA interference
CN102304570B (zh) 2002-11-13 2015-01-21 托马斯杰斐逊大学 用于癌症诊断和治疗的组合物和方法
JP5479663B2 (ja) 2002-12-20 2014-04-23 セレラ コーポレーション 心筋梗塞に関連する遺伝的多型、その検出方法および使用
AU2004215097A1 (en) 2003-02-10 2004-09-10 National Institute Of Advanced Industrial Science And Technology Regulation of gene expression by DNA interference
US8145436B2 (en) 2003-07-15 2012-03-27 The Trustees Of The University Of Pennsylvania Method and systems for identifying micro-RNA targets and synthesizing novel micro-RNAs and uses of the same
CA2533701A1 (en) 2003-07-31 2005-02-17 Isis Pharmaceuticals, Inc. Oligomeric compounds and compositions for use in modulation of small non-coding rnas
WO2005047505A2 (en) 2003-08-07 2005-05-26 Whitehead Institute For Biomedical Research Methods and products for expression of micro rnas
WO2005017145A1 (ja) 2003-08-13 2005-02-24 Japan Biological Informatics Consortium 機能性ｒｎａが制御する被制御遺伝子の同定・予測方法及びその利用方法
WO2005028648A1 (ja) 2003-09-22 2005-03-31 Aichi Prefecture リンパ腫の病型および予後診断方法
BRPI0415496A (pt) 2003-10-14 2006-12-26 Novartis Ag microdisposição de oligonucleotìdeo
EP1691891A2 (en) 2003-11-13 2006-08-23 The Board Of Regents, The University Of Texas System Inhibition of trp channels as a treatment for cardiac hypertrophy and heart failure
US7674617B2 (en) 2003-12-15 2010-03-09 College of Medicine, Pochon Cha University Industry -Academic Cooperation Foundation MiRNA molecules isolated from human embryonic stem cell
US20050256072A1 (en) 2004-02-09 2005-11-17 University Of Massachusetts Dual functional oligonucleotides for use in repressing mutant gene expression
WO2005078139A2 (en) 2004-02-09 2005-08-25 Thomas Jefferson University DIAGNOSIS AND TREATMENT OF CANCERS WITH MicroRNA LOCATED IN OR NEAR CANCER-ASSOCIATED CHROMOSOMAL FEATURES
US7772389B2 (en) 2004-02-13 2010-08-10 Rockefeller University Anti-microRNA oligonucleotide molecules
US8088902B2 (en) 2004-04-05 2012-01-03 The Rockefeller University DNA virus microRNA and methods for inhibiting same
US20060134639A1 (en) 2004-04-06 2006-06-22 Huffel Christophe V Method for the determination of cellular transcriptional regulation
US20050260648A1 (en) 2004-04-06 2005-11-24 Huffel Christophe V Method for the determination of cellular transcriptional
CN1961081B (zh) 2004-04-07 2012-09-05 埃克斯魁恩公司 用于定量微rna和小干扰rna的新方法
EP2471922A1 (en) 2004-05-28 2012-07-04 Asuragen, Inc. Methods and compositions involving microRNA
EP2990410A1 (en) 2004-08-10 2016-03-02 Alnylam Pharmaceuticals Inc. Chemically modified oligonucleotides
JP2008511678A (ja) 2004-09-02 2008-04-17 イェール ユニバーシティ マイクロｒｎａによるオンコジーンの調節
FR2877350B1 (fr) 2004-11-03 2010-08-27 Centre Nat Rech Scient IDENTIFICATION ET UTILISATION DE miRNAs IMPLIQUES DANS LA DIFFERENCIATION DE CELLULES ISSUES D'UNE LEUCEMIE MYELOIDE
WO2008073922A2 (en) 2006-12-08 2008-06-19 Asuragen, Inc. Functions and targets of let-7 micro rnas
EP2322616A1 (en) 2004-11-12 2011-05-18 Asuragen, Inc. Methods and compositions involving miRNA and miRNA inhibitor molecules
WO2006063356A1 (en) 2004-12-10 2006-06-15 Isis Phamaceuticals, Inc. Regulation of epigenetic control of gene expression
US20060185027A1 (en) 2004-12-23 2006-08-17 David Bartel Systems and methods for identifying miRNA targets and for altering miRNA and target expression
US20060166920A1 (en) 2005-12-27 2006-07-27 Regents Of The University Of Michigan Oligonucleotide based therapeutics
US20070099196A1 (en) 2004-12-29 2007-05-03 Sakari Kauppinen Novel oligonucleotide compositions and probe sequences useful for detection and analysis of micrornas and their target mRNAs
US8071306B2 (en) 2005-01-25 2011-12-06 Merck Sharp & Dohme Corp. Methods for quantitating small RNA molecules
US20070065840A1 (en) 2005-03-23 2007-03-22 Irena Naguibneva Novel oligonucleotide compositions and probe sequences useful for detection and analysis of microRNAS and their target mRNAS
JP2006292367A (ja) 2005-04-05 2006-10-26 Mitsubishi Rayon Co Ltd ｍｉＲＮＡ検出用マイクロアレイ
WO2006108581A2 (en) 2005-04-15 2006-10-19 Cenix Bioscience Gmbh Human marker genes and agents for cardiovascular disorders and artherosclerosis
WO2006111512A1 (en) 2005-04-19 2006-10-26 Basf Plant Science Gmbh Improved methods controlling gene expression
CA2609142C (en) 2005-05-27 2016-02-09 Fondazione Centro San Raffaele Del Monte Tabor Therapeutic gene vectors comprising mirna target sequences
US20070054287A1 (en) 2005-05-31 2007-03-08 Applera Corporation Method for identifying medically important cell populations using micro rna as tissue specific biomarkers
CA2610265A1 (en) 2005-05-31 2007-05-10 Cold Spring Harbor Laboratory Methods for producing micrornas
US20090209621A1 (en) 2005-06-03 2009-08-20 The Johns Hopkins University Compositions and methods for decreasing microrna expression for the treatment of neoplasia
CA2618995A1 (en) 2005-08-10 2007-02-22 The Rockefeller University Antagomirs for use in inhibiting mir-122
US20070213292A1 (en) 2005-08-10 2007-09-13 The Rockefeller University Chemically modified oligonucleotides for use in modulating micro RNA and uses thereof
CN101426912A (zh) 2005-08-17 2009-05-06 瑟纳治疗公司 介导rna干扰的化学修饰短干扰核酸分子
EP1937280B1 (en) 2005-09-12 2014-08-27 The Ohio State University Research Foundation Compositions for the therapy of bcl2-associated cancers
US20070092882A1 (en) 2005-10-21 2007-04-26 Hui Wang Analysis of microRNA
WO2007056826A1 (en) 2005-11-21 2007-05-24 Johnson & Johnson Research Pty Limited Multitargeting interfering rnas and methods of their use and design
WO2007087451A2 (en) 2006-01-25 2007-08-02 University Of Massachusetts Compositions and methods for enhancing discriminatory rna interference
JP2009524430A (ja) 2006-01-26 2009-07-02 ユニバーシティ オブ マサチューセッツ 治療的使用のためのｒｎａ干渉剤
WO2007092181A2 (en) 2006-01-26 2007-08-16 Unversity Of Massachusetts Compositions and methods for modulating translational repression
US8129515B2 (en) 2006-01-27 2012-03-06 Isis Pharmaceuticals, Inc. Oligomeric compounds and compositions for the use in modulation of microRNAs
EP1986697B1 (en) 2006-02-17 2016-06-29 GE Healthcare Dharmacon, Inc. Compositions and methods for inhibiting gene silencing by rna interference
EP2522746B1 (en) 2006-03-02 2014-11-12 The Ohio State University Research Foundation MicroRNA expression profile associated with pancreatic cancer
CA3024953A1 (en) 2006-04-03 2007-10-11 Roche Innovation Center Copenhagen A/S Pharmaceutical composition comprising anti-mirna antisense oligonucleotides
US20080220423A1 (en) 2006-05-19 2008-09-11 Soren Moller Oligonucleotide probes useful for detection and analysis of microRNA precursors
WO2007147067A2 (en) 2006-06-14 2007-12-21 Rosetta Inpharmatics Llc Methods and compositions for regulating cell cycle progression
WO2007147409A2 (en) 2006-06-19 2007-12-27 Københavns Universitet Ribozyme mediated stabilization of polynucleotides
WO2008024499A2 (en) 2006-08-25 2008-02-28 Duke University Methods for in vivo identification of endogenous mrna targets of micrornas
WO2008036776A2 (en) 2006-09-19 2008-03-27 Asuragen, Inc. Mir-15, mir-26, mir -31,mir -145, mir-147, mir-188, mir-215, mir-216 mir-331, mmu-mir-292-3p regulated genes and pathways as targets for therapeutic intervention
WO2008042231A2 (en) 2006-09-29 2008-04-10 Children's Medical Center Corporation Compositions and methods for evaluating and treating heart failure
WO2008043521A2 (de) 2006-10-09 2008-04-17 Julius-Maximilians-Universität Würzburg Microrna (mirna) zur diagnose und therapie von herzerkrankungen
WO2008147430A2 (en) 2006-10-11 2008-12-04 Nucleonics, Inc. Microrna-formatted multitarget interfering rna vector constructs and methods of using the same
JP2010509923A (ja) 2006-11-23 2010-04-02 ミルクス セラピューティクス アンパーツゼルスカブ 標的ｒｎａの活性を変化させるためのオリゴヌクレオチド
WO2008073921A2 (en) 2006-12-08 2008-06-19 Asuragen, Inc. Mir-126 regulated genes and pathways as targets for therapeutic intervention
EP2102341A2 (en) 2006-12-08 2009-09-23 Asuragen, INC. Mirna regulated genes and pathways as targets for therapeutic intervention
WO2008073920A2 (en) 2006-12-08 2008-06-19 Asuragen, Inc. Mir-21 regulated genes and pathways as targets for therapeutic intervention
WO2008074328A2 (en) 2006-12-21 2008-06-26 Exiqon A/S Microrna target site blocking oligos and uses thereof
EP3536788A1 (en) 2006-12-21 2019-09-11 QIAGEN GmbH Microrna target site blocking oligos and uses thereof
US20090175827A1 (en) 2006-12-29 2009-07-09 Byrom Mike W miR-16 REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTION
US20080287383A1 (en) 2007-03-02 2008-11-20 Nastech Pharmaceutical Company Inc. Nucleic acid compounds for inhibiting erbb gene expression and uses thereof
WO2008112226A2 (en) 2007-03-13 2008-09-18 Massachusetts Institute Of Technology Cre-lox based gene knockdown constructs and methods of use thereof
US8288358B2 (en) 2007-03-26 2012-10-16 Newcastle Innovation Ltd. Therapeutic targets and molecules
CA2687336C (en) 2007-05-23 2014-12-23 Dharmacon, Inc. Micro-rna scaffolds and non-naturally occurring micro-rnas
CA2693031A1 (en) 2007-07-18 2009-01-22 The Regents Of The University Colorado Differential expression of micrornas in nonfailing versus failing human hearts
WO2009012263A2 (en) 2007-07-18 2009-01-22 The Trustees Of Columbia University In The City Of New York Tissue-specific micrornas and compositions and uses thereof
US20090092980A1 (en) 2007-07-20 2009-04-09 Christoph Arenz miRNA PROCESSING INHIBITOR EFFICACY ASSAYS AND SUBSTANCES
WO2009044895A1 (ja) 2007-10-03 2009-04-09 Kyowa Hakko Kirin Co., Ltd. 標的遺伝子の発現を抑制する組成物
AU2008306327B2 (en) 2007-10-04 2014-05-15 Roche Innovation Center Copenhagen A/S Micromirs
WO2009058818A2 (en) 2007-10-29 2009-05-07 The Board Of Regents Of The University Of Texas System Compositions comprising a micro-rna and methods of their use in regulating cardiac remodeling
US8389485B2 (en) 2007-10-29 2013-03-05 University Of Massachusetts Encapsulated nanoparticles for nucleic acid delivery
MX2010005166A (es) 2007-11-09 2010-10-07 Univ Texas Micro arn de la familia mir-15 que modulan la sobrevivencia de cardiomiocitos y reparacion cardiaca.
EP2268811A1 (en) 2008-03-07 2011-01-05 Santaris Pharma A/S Pharmaceutical compositions for treatment of microrna related diseases
EP2105145A1 (en) 2008-03-27 2009-09-30 ETH Zürich Method for muscle-specific delivery lipid-conjugated oligonucleotides
EP2279267A4 (en) 2008-03-27 2012-01-18 Vascular Biosciences Inc METHOD FOR IDENTIFICATION OF NEW THERAPEUTIC CANDIDATES VIA GENE EXPRESSION ANALYSIS IN VASCULAR DISEASES
US20100113284A1 (en) 2008-04-04 2010-05-06 Alexander Aristarkhov Small interfering rna (sirna) target site blocking oligos and uses thereof
US20090326049A1 (en) 2008-04-04 2009-12-31 Alexander Aristarkhov Blocking oligos for inhibition of microrna and sirna activity and uses thereof
US8258111B2 (en) 2008-05-08 2012-09-04 The Johns Hopkins University Compositions and methods related to miRNA modulation of neovascularization or angiogenesis
WO2009149182A1 (en) 2008-06-04 2009-12-10 The Board Of Regents Of The University Of Texas System Modulation of gene expression through endogenous small rna targeting of gene promoters
WO2010036939A2 (en) 2008-09-26 2010-04-01 University Of Southern California A system for synergistic expression of multiple small functional rna elements
EP2447274B1 (en) 2008-10-24 2017-10-04 Ionis Pharmaceuticals, Inc. Oligomeric compounds and methods
WO2010126355A1 (en) 2009-04-29 2010-11-04 Academisch Medisch Centrum Bij De Universiteit Van Amsterdam Means and methods for counteracting, preventing and/or determining heart failure, or a risk of heart failure
CA2765129A1 (en) 2009-06-08 2010-12-16 Miragen Therapeutics Chemical modification motifs for mirna inhibitors and mimetics

Also Published As

Publication number Publication date
AR091539A1 (es) 2015-02-11
CA2876105A1 (en) 2013-12-27
EP2863956A1 (en) 2015-04-29
BR112014032239A2 (pt) 2017-08-01
TW201406774A (zh) 2014-02-16
IN2014DN10899A (ro) 2015-09-11
EA201590070A1 (ru) 2015-04-30
CN104540527A (zh) 2015-04-22
WO2013192486A1 (en) 2013-12-27
JP2015525081A (ja) 2015-09-03
AU2013277033A1 (en) 2015-01-22
US20130345288A1 (en) 2013-12-26
EP2863956A4 (en) 2016-01-20
MX2014015641A (es) 2015-07-14
US9163235B2 (en) 2015-10-20
HK1209621A1 (en) 2016-04-08
SG11201408460UA (en) 2015-01-29
KR20150036140A (ko) 2015-04-07

Similar Documents

Publication Publication Date Title
MD20150006A2 (ro) Inhibitori de micro-ARN din familia miR-15
MX2013005875A (es) Inhibidores de microarn que comprenden nucleotidos bloqueados.
MX355408B (es) Inhibidores a base de oligonucleotidos que comprenden un motivo de acido nucleico bloqueado.
PH12017501501A1 (en) Compositions and methods for inhibiting expression of tmprss6 gene
MX2021015290A (es) Composiciones y metodos para inhibicion de genes para apolipoproteina c-iii (apoc3).
MX2019012252A (es) Composiciones y metodos para inhibir la expresion del gen alas1.
NZ797319A (en) Modified rnai agents
UA117098C2 (uk) Сполука, що містить модифікований олігонуклеотид
MX2019006413A (es) Composiciones de arni de serpinc1 y metodos de uso de las mismas.
SG194751A1 (en) Compositions and methods for inhibiting gene expression of hepatitis b virus
WO2012142313A8 (en) Micro-rna inhibitors and their uses in disease
MX2022001017A (es) Composiciones y metodos para inhibir la expresion del gen de sintasa de acido 5'-aminolevulinico 1 (alas1).
IN2014CN03921A (ro)
MX2018006445A (es) Oligonucleotidos antisentido de interleucina-34 (il-34) y metodos de uso de los mismos.
PL398796A1 (pl) Zastosowanie czasteczek miRNA oraz antagomiru dla miRNA w diagnostyce, zapobieganiu i leczeniu stwardnienia rozsianego
NZ728207A (en) Oligonucleotide-based inhibitors comprising locked nucleic acid motif
NZ776080A (en) Modified rnai agents
TW201129365A (en) Compositions and methods for inhibiting expression of IKK2 genes
MA37789A1 (fr) Inhibiteurs de la famille mir-15 de micro-arn

Legal Events

Date Code Title Description
FA9A Abandonment or withdrawal of application (patent for invention)